2012Annual &Special

M ti
MeetingofShareholders
f Sh h ld
May8,2013

Agenda
1.
2.
3.
4.
5.
6.
7.
8.
9.
10
10.
11.
12.
13.

OpeningoftheMeeting
ChairmanandSecretary
Scrutineers
NoticeofMeeting
ReportoftheScrutineers
MinutesofthelastMeeting
ConsolidatedFinancialStatementsandAuditorsReport
R ifi i
RatificationoftheactsoftheDirectors
f h
f h Di
ElectionofDirectors
Appointment of Auditors and Fixing of their Remuneration
AppointmentofAuditorsandFixingoftheirRemuneration
Increaseofmaximumofcommonsharesreservedforissuance
undertheamendedandrestatedstockoptionplan
p
p
RenewaloftheamendedandrestatedProMetic loanagreement
2
Varia

Corporate
p
Presentation

ForwardLookingStatement/Copyrightnotice
/ Disclaimer
/Disclaimer
ForwardLookingStatement
This presentation contains forwardlooking statements about ProMetics objectives, strategies and businesses
that involve risks and uncertainties. These statements are forwardlooking because they are based on our
current expectations about the markets we operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these forwardlooking statements if known or unknown
risks
i k affect
ff t our business,
b i
or if our estimates
ti t or assumptions
ti
t
turn
outt to
t be
b inaccurate.
i
t Such
S h risks
i k and
d
assumptions include, but are not limited to, ProMetics ability to develop, manufacture, and successfully
commercialize valueadded pharmaceutical products, the availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of
business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could cause
actual events or results to materially differ from our current expectations in the Annual Information Form for the
year ended December 31, 2012, under the heading Risk Factors. As a result, we cannot guarantee that any
forwardlooking statement will materialize. We assume no obligation to update any forwardlooking statement
even if new information becomes available, as a result of future events or for any other reason, unless required
by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

Copyright notice
The information contained in this presentation (including names, images, logos and descriptions portraying
ProMetic's products and/or services) is the property of ProMetic Life Sciences Inc., of its divisions and / or of its
subsidiaries (ProMetic) and is protected by copyright, patent and trademark law and / or other intellectual
property rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by any
means, electronic or mechanical, including printing and photocopying, or by any information storage or retrieval
system without prior permission in writing from ProMetic.
Disclaimer
ProMetic reserves the right to make improvements, corrections and/or changes to this presentation at any time.

ProMeticLifeSciencesInc.

Introduction
d i
2012FinancialResults
B i
BusinessSegments:
S
t

Smallmoleculetherapeutics
Protein Technologies:
ProteinTechnologies:

Bioseparation /filters

Plasmaderivedproteins

Q12013
2013Business:BaseCase
Outlook
l k
2013Objectives

QuestionandAnswerPeriod

2012FinancialResults

SourceofFinancialInformation
The following information is derived from the audited
consolidated December 31, 2012 financial information
and on the statutory financial statements for 2011,
both of which were prepared in accordance with
International Financial Reporting Standards (IFRS).
Further financial information,, includingg the ProMetics
Annual Information Form, is available on SEDAR
(www.sedar.com).
All tabulated sums are in CAD 000s except for per
share amounts or where indicated.
7

FinancialPerformancefor2012
Significantly
improved
financial
performance in 2012 with record
revenues of $23.3 million exceeding
anticipated base case of $21.0
million.
Product
P d t sales
l
off $11.6
$11 6 million,
illi
Services revenues of $5.3 million and
Licensing revenues totalling $6.4
million.

Stronger
g
total revenues and cost
containment positively impacted
EBITDA.
First EBITDA positive year in corporate
history at $2.5
$ million.
8

ComparisonofKeyFinancials:P&L
YearendedDecember31
2012
CAD 000s
CAD000s
23,321

2011
CAD 000s
CAD000s
17,589

5,326

1,854

10 310
10,310

11 230
11,230

Administration&Marketing

5,966

5,789

FinanceCosts

1,483

1,363

NetLoss

(424)

(3,267)

NetLosspershare(basicanddiluted)

(0.00)

(0.01)

EBITDA*

2,498

(526)

Revenues
CostofGoods
Total Research & Development Costs
TotalResearch&DevelopmentCosts

*EBITDA is a nonGAAP measure, employed by the corporation to monitor its performance. Therefore it is unlikely to be
comparable to similar measures presented by other companies. The corporation calculates its EBITDA by subtracting from
R
Revenues,
it Cost
its
C t off Goods
G d Sold,
S ld its
it Research
R
h and
d Development
D l
t Expenses
E
R h
Rechargeable
bl and
d NonRechargeable
N R h
bl as wellll as its
it
Administration and Marketing Expenses and excluding amortization of capital assets and licenses and patents.
9

ComparisonofKeyFinancials:
B l
BalanceSheet
Sh t
YearendedDecember31
2012
CAD000s
1,205

2011
CAD000s
275

Accounts Receivable
AccountsReceivable

4,750

1,438

ShareSubscriptionReceivable

9,822

BankandOtherLoans

(1,636)

(752)

Trade&OtherPayables

(5,094)

(7,091)

DeferredRevenues

(2,355)

(447)

LongtermDebtProvidedbyShareholders

(4,017)

(4,161)

AdvanceonRevenuesfromaSupplyAgreement

(3,030)

(3,063)

5,819

(8,568)

22,991

8,692

Cash

NetEquity(Deficiency)
BalanceSheetTotalAssets

10

BusinessSegment:
SmallMolecule Therapeutics

USRDS2012AnnualDataReport
Medicare Population 2010

Medicare Costs 2010

12

RegulatoryStrategy
PBI4050
NewDatatobepresentedat
KeyRegulatoryFilingMilestones&Timing:IVIG

InternationalConferences
l
f

ERAEDTA(EuropeanRenalAssociation EuropeanDialysisand
TransplantAssociation):Istanbul,1821May,2013.
WorldCongress
W ld C
ofNephrology:HongKong,31May
fN h l
H
K
31 M
4J
4June,2013.
2013
Americanassociationforthestudyofliverdiseases:Washington15
November , 2013
November,2013
AmericanSocietyofNephrology:Atlanta,November11,2013
A
AmericanAssociationRespirology
i
A
i ti R i l
C
Convention:Anaheim,November16
ti
A h i N
b 16
2013

14

PhasesinDrugDevelopment&
Relativevalue/ProbabilityofregulatoryApproval

Probabilityy

Value

$5000M

Regulatory
Filing

PhIII

100%

75%

Ph II

$500M

50%
Ph Ib /II
PhIb
/ II

PhI

$50M

R&D
Discovery

Preclinical
Proofofconcept

GLPTOX
GMPAPI
INDfilings
fili

+$250M
10%
$1.5M

2013

DevelopmentMilestoneTimelines
p
PreINDMeeting
FDA/EMA/
Health
Canada
HealthCanada
2013
Q1

Q2

Q3

CTA
Health
Canada
Q4

IND FDA
CTA
2014
Q1

Techtransferchemicalsynthesis
Tech transfer chemical synthesis
Chemicalsynthesisscaleup
GMPManufacturinginFDAplant
Pharmaco kinetics
GLP T i l
GLPToxicologyProgram
P
Finaldosageformulation
PhaseI
Healthy
volunteers
l t

PhaseIb II
Patients

BusinessSegment:
g
Protein Technologies

Bioseparation
Enables
Enablesthecaptureofmultipletargetedproteinsdirectlyfrom
the capture of multiple targeted proteins directly from
varioussourceproducts
Providesforahighlyefficientandcosteffectiveseparation
processfromotherproteinsandimpuritiesdeliveringhighyields
ofpurifiedproduct
Resultsinsignificantreductionsinclient
Results in significant reductions in clientsscostofgoodsand
cost of goods and
costsassociatedtodrugpurification.

Protein PowerHouse

InitiationofacollaborativeagreementinJanuary2003tocodevelopanovelprocesstorecover
therapeutic proteins in a sequential manner from plasma
therapeuticproteinsinasequentialmannerfromplasma.
CollaborationrelyingonProMetic's MimeticLigandstechnologiesandAmericanRedCross's
uniquecompetenciesinplasmaandbloodproducts,processandanalyticaldevelopment.
Resultedinthedevelopmentofaprocess(PPPS)capableofextractingsomeofthemost
valuableproteinsfromplasmaatmuchhigheryieldsthanotherprocesses.

PlasmaProteins

75% ofrevenuesaregeneratedwith4proteins:
Albumin,IgG,FactorVIIIandAAT

74%ofrevenuesareusedby16%ofpopulation(NA,EU)

What is PPPSTM?

Multiproductsequentialpurificationprocessoriginallydevelopedwith ARC.
Proprietary platformderivedfromtheuseofPBLaffinitytechnology.
DevelopedandcommercializedbyProMetics USbasedsubsidiary,PBT
Using powerful affinity separation materials to extract and purify commercially
Usingpowerfulaffinityseparationmaterialstoextractandpurifycommercially
valuableplasmaproteinsinhighyield.
Highlyefficientinextractingandpurifyingtherapeuticproteinsfromhuman
plasma to develop best in class biotherapeutic
plasmatodevelopbestinclassbio
therapeuticproducts.
products

PPPSTM:TheBenefits
: The Benefits

Improvedeconomicsoverindustryaverages,through:
improvedrecoveryyield,
smallerfootprintforsamemanufacturingoutput,
moreproductfromlessplasma
more product from less plasma

Improvedpurity

Improvedsafety pathogenremovalandviralinactivation

Recoveryofvaluableproteinstargetingrarediseases,potentially
resultinginproductswithOrphanDrugDesignation

PPPSTM:TheProcess
: The Process

TurnKeyProcess

PPPSTM:TheProducts&Market
Opportunities

25

Orphan DrugDesignation
Drug Designation

Noveldrugsorbiologics
g
g
Treatmentofararediseaseorcondition
g
p
Affectingfewerthan200,000patientsintheUS.
SevenyearperiodofU.S.marketingexclusivityupon
marketingapproval
Taxcreditsforclinicalresearchcosts
Abilitytoapplyforannualgrantfunding
Clinicalresearchtrialdesignassistance
l
l
h
ld
Waiverofprescriptiondruguserfees.

TYPE1Plasminogen Deficiency

Plasminogen: Plasminogen is a naturally occurring protein synthesized by

the liver and circulates in the blood. Plasmin is involved in wound healing,
cell migration, tissue remodeling, angiogenesis and embryogenesis.

Type 1 Plasminogen Deficiency: One of the most welldefined conditions

associated with plasminogen deficiency is ligneous conjunctivitis, which is
characterized by thick, woody (ligneous) growths on the conjunctiva of the
eye, and
d if left
l ft untreated,
t t d can lead
l d to
t blindness.
bli d
M t affected
Most
ff t d cases are
infants and children

Hypoplasminogenemia: multisystem disease that can also affect the ears,

ears
sinuses, tracheobronchial tree, genitourinary tract, and gingiva.

OrphanDrugDiseasesTakingFrontStage

TheNationalInstitutesofHealthestimatesthatthereareapproximately
7,0008,000rarediseasesaffecting25millionAmericans.Ararediseaseis
definedasaconditionaffectingfewerthan200,000peopleintheUnited
States.
States

10drugs

TheOrphanDrugAct(ODA)enactedin1983hasincreasedfrom
in1983to

382 in2011
>2,500

UndertheODA,
medicineshavebeendesignatedorphan
drugsandareinallstagesofdevelopment
Orphandrugscurrentlymakeup
Inthelast3years,
diseases

22% oftotaldrugsales

35% ofFDAapproveddrugswereforOrphan

In2011,35newmedicineswereapprovedbytheFDA:24NCEs,6

11 ofthenewmedicines

therapeuticbiologics,andfiveotherbiologics.
areorphandrugs.
h d

WeBelieve:InbuildingShareholderValue
Sales of Biopharmaceuticals

Sales of Bulk Active Ingredients

Royalties on Licencees' sales of

Biopharmaceuticals
Sales of Affinity Resins to
Licensees

10

20

30

40

50

60

70

80

90 100

29

Q
Q12013FinancialResults

ComparisonofKeyFinancials:P&L
Q12013
Q12013
CAD 000s
CAD000s
4,445

Q12012
CAD 000s
CAD000s
1,059

CostofGoods

1,347

916

Total Research & Development Costs

TotalResearch&DevelopmentCosts

3 098
3,098

2 535
2,535

Administration&Marketing

1,519

1,397

354

352

(2,093)

(4,571)

(0.00)

(0.01)

(1,321)

(3,581)

Revenues

FinanceCosts
NetLoss
NetLosspershare(basicanddiluted)
EBITDA*

*EBITDA is a nonGAAP measure, employed by the corporation to monitor its performance. Therefore it is unlikely to be
comparable to similar measures presented by other companies. The corporation calculates its EBITDA by subtracting from
R
Revenues,
it Cost
its
C t off Goods
G d Sold,
S ld its
it Research
R
h and
d Development
D l
t Expenses
E
R h
Rechargeable
bl and
d NonRechargeable
N R h
bl as wellll as its
it
Administration and Marketing Expenses and excluding amortization of capital assets and licenses and patents.
31

ComparisonofKeyFinancials:
B l
BalanceSheet
Sh t
Mar312013
CAD000s
7,549

Dec312012
CAD000s
1,205

3,695

4,750

9,822

2,498

1,238

700

1,636

Trade&OtherPayables

5,041

5,094

DeferredRevenues

1,212

2,355

LongtermDebtProvidedbyShareholders

3,135

4,017

AdvanceonRevenuesfromaSupplyAgreement

2,919

3,030

NetEquity

6,258

5,819

Cash
Accounts Receivable
AccountsReceivable
ShareSubscriptionReceivable
Inventories
BankandOtherLoans

32

Estimated
2013 Revenue vs. 2012
Estimated2013Revenuevs.2012
$Million
n

30
25
20
2012

15

E. 2013
E.2013
10
5
0
H1

H2

YEAR

E.2013aheadof2012by~$3,3MinQ1

$Million

PotentialRevenueMix
120
100
80
60
40
20
0
2013

2014

2015

Salesofaffinity filters /bioseparation products

Productdevelopment servicerevenues
Plasmaderived proteins /biopharmaceuticals

2016

2017

$250M

$200M

ProMetics totalrevenuesfromthe
ProteinTechnologiessegmentwillbe
influencedbytheexactmixof:

$150M

Productsmanufacturedforlicenseesand
Marketedbylicensees
Royaltiesfromlicensees
Products manufactured and marketed by
Productsmanufacturedandmarketedby
ProMetic &marketingpartners

200820092010201120122013201420152016

$100M

$50M

201720182019

Key2013Objectives

Plasmaderived Therapeutics:
OperationallaunchofProMeticBioProductionInc.
Secureorphan drug designations

SmallMolecule Therapeutics:
Advanceleadcompoundtoclinicaltrialstage
Ad
l d
d t li i l t i l t
Developandenterintonewprograms/strategicalliances

QUESTIONAND
Q
ANSWERPERIOD